 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
34 News |  |
- | p53MVA - Tara I / O
Trial completion date: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Oct 8, 2024
P2, N=29, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Aug 2024 --> Dec 2024
- | p53MVA - Tara I / O
Trial completion date, Trial primary completion date: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - May 2, 2024
P2, N=29, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Aug 2024 --> Dec 2024 Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
- | p53MVA - Tara I / O
Trial completion date, Combination therapy: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Mar 19, 2024
P1, N=11, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024 Trial completion date: Dec 2023 --> Dec 2024
- | p53MVA - Tara I / O
Trial completion date, Trial primary completion date: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jan 2, 2024
P2, N=29, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- | Keytruda (pembrolizumab) / Merck (MSD), p53MVA - Tara I / O
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer. (Pubmed Central) - Nov 30, 2023
p53MVA/pembrolizumab immunotherapy showed promising anti-tumor activity in patients who demonstrated functionally competent peripheral blood T cells. Detection of markers of terminally differentiated T cells before treatment may identify patients unlikely to respond to p53MVA/pembrolizumab.
- | p53MVA - Tara I / O
Enrollment change, Trial completion date, Combination therapy: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Mar 21, 2023
P1, N=11, Active, not recruiting, Sponsor: City of Hope Medical Center
Detection of markers of terminally differentiated T cells before treatment may identify patients unlikely to respond to p53MVA/pembrolizumab. N=19 --> 11 | Trial completion date: Dec 2022 --> Dec 2023
- ||| Keytruda (pembrolizumab) / Merck (MSD), p53MVA - Tara I / O
How close are these to trial in the UK, particularly the P53mva with Pembro? @cancermedic (Twitter) - Jan 25, 2023
- | p53MVA - Tara I / O
Enrollment closed, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Sep 30, 2022
P2, N=29, Active, not recruiting, Sponsor: City of Hope Medical Center
N=19 --> 11 | Trial completion date: Dec 2022 --> Dec 2023 Recruiting --> Active, not recruiting
- | p53MVA - Tara I / O
Trial completion date, Combination therapy: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Mar 18, 2022
P1, N=19, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> Dec 2022
- | p53MVA - Tara I / O
Trial completion date, Trial primary completion date, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 21, 2022
P2, N=28, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2021 --> Dec 2022 Trial completion date: Jan 2022 --> Dec 2023 | Trial primary completion date: Jan 2022 --> Dec 2023
- | p53MVA - Tara I / O
Trial completion date, Combination therapy: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Mar 10, 2021
P1, N=19, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jan 2022 --> Dec 2023 | Trial primary completion date: Jan 2022 --> Dec 2023 Trial completion date: Feb 2020 --> Dec 2021
- | p53MVA - Tara I / O
Trial completion date, Trial primary completion date, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 11, 2021
P2, N=28, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Feb 2020 --> Dec 2021 Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
- ||||| p53MVA - Tara I / O
#ASH20 #leusm Stahl: Low rate of MRD clearance after 7+3 w DNMT3A, RUNX1, SF3B1, TP53. Latter three predict low chance of MRD clearance pre-allo. In MVA P53, DNMT3A, RUNX1, and SG3F1 remain predictors of poor response. Higher chance of MRD clearance with NPM1, CEBPA, Kit NRAS. (Twitter) - Dec 5, 2020
- | p53MVA - Tara I / O
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 23, 2020
P2, N=28, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022 Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2020 --> Feb 2021
- | gemcitabine / generics
Clinical, Journal: p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy. (Pubmed Central) - Oct 2, 2019
However, elevated p53-reactive CD4+ and CD8+T cell responses post therapy correlated with longer PFS. Therefore, if responses to p53MVA could be enhanced with alternative agents, superior clinical responses may be achievable.
- | Keytruda (pembrolizumab) / Merck (MSD), p53MVA - Tara I / O
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. (Pubmed Central) - May 22, 2019
Therefore, if responses to p53MVA could be enhanced with alternative agents, superior clinical responses may be achievable. We have shown that the combination of p53MVA vaccine with pembrolizumab is feasible, safe, and may offer clinical benefit in select group of patients that should be identified through further studies.
- | p53MVA - Tara I / O
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Apr 30, 2019
P1, N=19, Active, not recruiting, Sponsor: City of Hope Medical Center
We have shown that the combination of p53MVA vaccine with pembrolizumab is feasible, safe, and may offer clinical benefit in select group of patients that should be identified through further studies. Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Feb 2020
- | p53MVA - Tara I / O
Enrollment open, PD(L)-1 Biomarker, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Apr 16, 2019
P2, N=28, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Feb 2020 Not yet recruiting --> Recruiting
- | p53MVA - Tara I / O
Trial initiation date, PD(L)-1 Biomarker, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Dec 31, 2018
P2, N=28, Not yet recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Initiation date: Dec 2018 --> Mar 2019
- | p53MVA - Tara I / O
New P2 trial, PD(L)-1 Biomarker, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Dec 16, 2018
P2, N=28, Not yet recruiting, Sponsor: City of Hope Medical Center
- | p53MVA - Tara I / O
Trial initiation date, PD(L)-1 Biomarker, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Oct 9, 2018
P2, N=28, Not yet recruiting, Sponsor: City of Hope Medical Center
Initiation date: Dec 2018 --> Mar 2019 Initiation date: Sep 2018 --> Dec 2018
- | p53MVA - Tara I / O
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Jun 4, 2018
P1, N=19, Active, not recruiting, Sponsor: City of Hope Medical Center
Initiation date: Sep 2018 --> Dec 2018 Trial completion date: Apr 2018 --> Feb 2019 | Trial primary completion date: Apr 2018 --> Feb 2019
- | p53MVA - Tara I / O
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Apr 30, 2018
P1, N=12, Completed, Sponsor: City of Hope Medical Center
Trial completion date: Apr 2018 --> Feb 2019 | Trial primary completion date: Apr 2018 --> Feb 2019 Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Apr 2018 | Trial primary completion date: Aug 2018 --> Apr 2018
- | p53MVA - Tara I / O
Trial initiation date, PD(L)-1 Biomarker, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Apr 5, 2018
P2, N=28, Not yet recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Apr 2018 | Trial primary completion date: Aug 2018 --> Apr 2018 Initiation date: Mar 2018 --> Jun 2018
- | p53MVA - Tara I / O
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 6, 2018
P2, N=28, Not yet recruiting, Sponsor: City of Hope Medical Center
Initiation date: Mar 2018 --> Jun 2018 Trial primary completion date: Nov 2019 --> Feb 2020 | Trial completion date: Nov 2019 --> Feb 2020
- | p53MVA - Tara I / O
Trial initiation date, PD(L)-1 Biomarker, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jan 2, 2018
P2, N=28, Not yet recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Nov 2019 --> Feb 2020 | Trial completion date: Nov 2019 --> Feb 2020 Initiation date: Nov 2017 --> Mar 2018
- | p53MVA - Tara I / O
Enrollment closed, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Dec 5, 2017
P1, N=19, Active, not recruiting, Sponsor: City of Hope Medical Center
Initiation date: Nov 2017 --> Mar 2018 Recruiting --> Active, not recruiting
- | p53MVA - Tara I / O
Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Aug 22, 2017
P1, N=9, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Aug 2018
- | p53MVA - Tara I / O
Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Aug 3, 2017
P2, N=28, Not yet recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Sep 2017 --> Aug 2018 Initiation date: Jun 2017 --> Nov 2017 | Trial primary completion date: Jun 2019 --> Nov 2019
- | p53MVA - Tara I / O
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Apr 4, 2017
P1, N=19, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Jun 2017 --> Nov 2017 | Trial primary completion date: Jun 2019 --> Nov 2019 Trial primary completion date: Apr 2017 --> Apr 2018
- p53MVA - Tara I / O
Enrollment closed, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Jan 12, 2017
P1, N=9, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Apr 2017 --> Apr 2018 Recruiting --> Active, not recruiting
- p53MVA - Tara I / O
Enrollment change, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Jan 11, 2017
P1, N=19, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting N=12 --> 19
- p53MVA - Tara I / O
Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Sep 19, 2016
P1, N=9, Recruiting, Sponsor: City of Hope Medical Center
N=12 --> 19 Trial primary completion date: Sep 2016 --> Sep 2017
- p53MVA - Tara I / O
Enrollment open, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Jun 18, 2016
P1, N=12, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Recruiting | Trial primary completion date: Nov 2016 --> Feb 2017
- p53MVA - Tara I / O
Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Mar 14, 2016
P1, N=9, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting | Trial primary completion date: Nov 2016 --> Feb 2017 Trial primary completion date: Jun 2016 --> Sep 2016
- p53MVA - Tara I / O
Enrollment closed, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Jan 27, 2016
P1, N=12, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jun 2016 --> Sep 2016 Recruiting --> Active, not recruiting
- p53MVA - Tara I / O
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Nov 14, 2015
P1, N=12, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Nov 2015 | Trial primary completion date: May 2017 --> Nov 2016
- p53MVA - Tara I / O
Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Nov 8, 2015
P1, N=12, Not yet recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Nov 2015 | Trial primary completion date: May 2017 --> Nov 2016 Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Oct 2016 --> May 2017
- p53MVA - Tara I / O
New P1 trial, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - May 4, 2015
P1, N=12, Not yet recruiting, Sponsor: City of Hope Medical Center
- p53MVA - Tara I / O
Enrollment open, Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Jan 20, 2015
P1, N=9, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Oct 2016 --> May 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2015 --> Jun 2016
- p53MVA - Tara I / O
New P1 trial, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Oct 27, 2014
P1, N=9, Not yet recruiting, Sponsor: City of Hope Medical Center
- p53MVA - Tara I / O
Enrollment change: Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer (clinicaltrials.gov) - Aug 20, 2013
P1, N=12, Completed, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2015 --> Jun 2016 N=15 --> 12
- p53MVA - Tara I / O
Trial completion: Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer (clinicaltrials.gov) - Aug 20, 2013
P1, N=12, Completed, Sponsor: City of Hope Medical Center
N=15 --> 12 Suspended --> Completed